Ian Tomlinson


Ian Tomlinson has over 25 years of experience in the lifesciences sector from academic research to biotech startup to big pharma.  He founded Domantis Limited with Sir Gregory Winter, which was acquired by GSK for $454million.  He then served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK.

He is currently Chair of the Board at the Stevenage Bioscience Catalyst, UK's first open innovation biomedical campus.  He is also Chairman of the Investment Committee for Apollo Therapeutics, a £40 million fund dedicated to turning academic biotechnologies into novel medicines in collaboration with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge.

Dr Tomlinson graduated from Trinity College, Cambridge, UK.  He then spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry.

Go back to Board and Team

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.